This regenerative medicine company is advancing stem cell technologies to create human therapeutics targeting liver and kidney diseases, diabetes, and cancer. Their preclinical pipeline includes human liver stem cells, functional pancreatic islets, and nano-extracellular vesicles, providing potential treatments for conditions that currently lack effective therapies.
Funding
$66.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, including liver and kidney diseases, diabetes, and cancer, lack effective therapies, creating a significant unmet medical need. Traditional treatment options are often limited in their ability to regenerate damaged tissues or address the underlying causes of these conditions.
Solution
This company is developing stem cell-based therapeutics to address diseases with limited treatment options. Their approach leverages human stem cell technologies to create regenerative medicine solutions. The company's preclinical pipeline includes human liver stem cells, functional pancreatic islets, and nano-extracellular vesicles. These assets are being developed as potential treatments for liver and kidney diseases, diabetes, and cancer.
Target Audience
The primary target audience includes patients suffering from liver and kidney diseases, diabetes, and cancer, as well as healthcare providers seeking innovative treatment options for these conditions.
Features
- Human liver stem cells for potential liver regeneration and repair
- Functional pancreatic islets for potential treatment of diabetes
- Nano-extracellular vesicles with regenerative properties
- Preclinical pipeline targeting liver and kidney diseases, diabetes, and cancer